Compare Flagstar Bank NA (FLG) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Sana Biotechnology Inc — how do they compare? Flagstar Bank NA trades at $11.45 (market cap $4.71B), while Sana Biotechnology Inc trades at $2.84 (market cap $836.71M). The key difference: Flagstar Bank NA is far larger — about 5.6× Sana Biotechnology Inc's market cap, and Flagstar Bank NA pays a 0.35% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 22 Days and Sana Biotechnology Inc for 23 Days on average.
| FLG | SANA | |
|---|---|---|
Market Cap | $4.71B | $836.71M |
Volume | 7,410,589 | 4,507,444 |
Sector | Financials | Health |
52-Week High | $15.36 | $5.92 |
52-Week Low | $10.72 | $2.68 |
Typical Hold Time | 22 Days | 23 Days |
Enterprise Value | $15.25B | $749.96M |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Flagstar Bank (FLG) trades at $11.44, up 1.24% with a bearish technical outlook despite recent earnings volatility. The company reported mixed quarterly results with Q2 2026 missing EPS estimates but maintains analyst optimism with a $17.07 consensus target. Fundamentals show improving profitability with net income turning positive in 2026, while valuation metrics present a mixed picture with high P/E but attractive P/B ratio of 0.62.
The stock offers potential upside from current depressed levels given the significant discount to book value and strong analyst buy ratings (60% consensus). Key risks include ongoing earnings volatility, competitive banking pressures, and the challenge of sustaining recent profitability improvements amid economic uncertainty.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
